Athira Pharma/$ATHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Athira Pharma
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Ticker
$ATHA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
26
ISIN
US04746L1044
Website
Athira Pharma Metrics
BasicAdvanced
$11M
-
-$2.06
3.05
-
Price and volume
Market cap
$11M
Beta
3.05
52-week high
$3.67
52-week low
$0.22
Average daily volume
209K
Financial strength
Current ratio
7.257
Quick ratio
6.677
Long term debt to equity
1.851
Total debt to equity
2.992
Management effectiveness
Return on assets (TTM)
-55.53%
Return on equity (TTM)
-110.70%
Valuation
Price to book
0.28
Price to tangible book (TTM)
0.28
Price to free cash flow (TTM)
-0.122
Growth
Earnings per share change (TTM)
-32.41%
3-year earnings per share growth (CAGR)
4.81%
What the Analysts think about Athira Pharma
Analyst ratings (Buy, Hold, Sell) for Athira Pharma stock.
Athira Pharma Financial Performance
Revenues and expenses
Athira Pharma Earnings Performance
Company profitability
Athira Pharma News
AllArticlesVideos
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
GlobeNewsWire·1 week ago
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
GlobeNewsWire·2 weeks ago
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Athira Pharma stock?
Athira Pharma (ATHA) has a market cap of $11M as of May 23, 2025.
What is the P/E ratio for Athira Pharma stock?
The price to earnings (P/E) ratio for Athira Pharma (ATHA) stock is 0 as of May 23, 2025.
Does Athira Pharma stock pay dividends?
No, Athira Pharma (ATHA) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Athira Pharma dividend payment date?
Athira Pharma (ATHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Athira Pharma?
Athira Pharma (ATHA) has a beta rating of 3.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.